X-Rx Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

X-Rx General Information

Description

Developer of a drug discovery platform intended to offer advanced small molecule medicines in inflammation, fibrosis, and oncology. The company's platform combines the power of DNA-encoded libraries with a virtual development model to discover novel therapeutics for difficult to treat diseases, enabling doctors to identify tractable blood cells.

Contact Information

Website
www.x-rxdiscovery.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Beaver Street
  • Waltham, MA 02453
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 100 Beaver Street
  • Waltham, MA 02453
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

X-Rx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Sep-2018 Completed Out of Business
1. Early Stage VC (Series A) 04-Jan-2013 Completed Startup
To view X-Rx’s complete valuation and funding history, request access »

X-Rx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view X-Rx’s complete cap table history, request access »

X-Rx Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

X-Rx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017228371-A1 Compositions and combinations of autotaxin inhibitors Inactive 04-Mar-2016
CA-3016081-A1 Compositions and combinations of autotaxin inhibitors Inactive 04-Mar-2016
EP-3423057-A1 Compositions and combinations of autotaxin inhibitors Inactive 04-Mar-2016
US-20190008835-A1 Compositions and combinations of autotaxin inhibitors Inactive 04-Mar-2016
US-20170037007-A1 Substituted n-(2-(amino)-2oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases Inactive 23-Apr-2014 C07D211/58
To view X-Rx’s complete patent history, request access »

Ready to get started?

Request a free trial

X-Rx FAQs

  • When was X-Rx founded?

    X-Rx was founded in 2012.

  • Where is X-Rx headquartered?

    X-Rx is headquartered in Waltham, MA.

  • What industry is X-Rx in?

    X-Rx’s primary industry is Drug Discovery.

  • Is X-Rx a private or public company?

    X-Rx is a Private company.

  • What is X-Rx’s current revenue?

    The current revenue for X-Rx is .

  • How much funding has X-Rx raised over time?

    X-Rx has raised $8.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »